Citations

Clear

9383 citation(s) found for "Thomas, PS".

Mid‐ to Late‐Life Changes in Plasma Biomarkers of Alzheimer's Disease Pathology and Neurodegeneration and Associations with Cortical Thickness: The Atherosclerosis Risk in Communities Study
Lu, Y, Walker, Keenan A., Sullivan, Kevin, Griswold, Michael E., Thyagarajan, Bharat, Mielke, Michelle M, Hughes, Timothy M., Knopman, David S., Sharrett, A. Richey, Mosley, Thomas H., Gottesman, Rebecca F., Jack, Clifford R., Coresh, Josef, Palta, P., Pike, James Russell , Walker, Keenan A. , Griswold, Michael , Thyagarajan, Bharat , Lutsey, Pamela L. , Hughes, Timothy M. , Knopman, David S. , Sharrett, A. Richey, Mosley, Thomas H. , Gottesman, Rebecca F. , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | January 8, 2026 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_106603 Get It

Abstract Background Plasma biomarkers show promise as a noninvasive method for measuring Alzheimer's disease pathology and neurodegeneration throughout the lifecourse. However, the relationship between longitudinal changes in these biomarkers and late‐life brain morphology in community‐dwelling populations requires further investigation. Method Between 2011 and 2013, 1,977 participants from the Atherosclerosis Risk in Communities Study received an adjudicated cognitive diagnosis and underwent 3 Tesla magnetic resonance imaging scans. Whole‐brain cortical thickness was quantified by Freesurfer. Stored plasma samples collected in midlife (1993‐95, mean age 59.0 years) and late‐life (2011‐13, mean age 76.8 years) from a subsample of 1,515 participants were assayed in 2022 using Quanterix SiMoA. The assay quantified amyloid‐β (Aβ)42/40, phosphorylated tau at threonine 181 ( p ‐Tau181), neurofilament light (NfL), and glial fibrillary acidic protein (GFAP). Linear regression models estimated the association of plasma biomarkers from midlife, late‐life, and the change from midlife to late‐life with cortical thickness in late‐life. Interactions and effect modification by age were examined in exploratory analyses. Result The sample (Table 1) included 920 (60.7%) women, 387 (25.5%) Black participants, 513 (33.9%) participants with mild cognitive impairment, and 85 (5.6%) participants with dementia. The average age in late‐life was 76.8 (5.3 SD) years and the average cortical thickness was 2.27 (0.11 SD) millimeters. Cortical thickness was lower in individuals with adjudicated mild cognitive impairment or dementia compared to individuals without cognitive impairment (2.25 mm versus 2.29 mm, p <0.0001). In models adjusted for demographics, lifestyle factors, cardiovascular factors, and the presence of APOE ε4 alleles, higher midlife measures of p ‐Tau181 and increases from midlife to late‐life in NfL and GFAP were associated with lower cortical thickness in late‐life (Table 2). Concurrent measures of plasma biomarkers in late‐life were associated with lower cortical thickness (Table 2) and exhibited a stronger association among participants ≥75 years compared to <75 years (Table 3). Conclusion Plasma biomarkers of Alzheimer's disease pathology and neurodegeneration obtained in midlife and late‐life were associated with late‐life differences in cortical thickness. Additional longitudinal research is needed to determine whether plasma biomarkers predict cortical thinning over time and may serve as an early indicator of accelerated brain atrophy.
The Impact of Sex in Tau‐related AD pathology
Botton, Lorenza Pabst, Bellaver, Bruna, Povala, Guilherme, Ferreira, Pamela C.L., Amaral, Lívia , Masdeu, Joseph C., Tudorascu, DL, Karikari, Thomas K, Soleimani‐Meigooni, David, Fortea, Juan M., Lowe, Val J. , Oh, Hwamee, Pascual, Belen, Gordon, Brian A., Rosa‐Neto, Pedro, Baker, Jess , Pascoal, Tharick A, Bellaver, Bruna , Povala, Guilherme , Ferreira, Pâmela C.L. , Bauer‐Negrini, Guilherme , Lussier, Firoza Zubeida , Masdeu, Joseph C , Tudorascu, Dana , Karikari, Thomas K. , Soleimani‐Meigooni, David N. , Fortea, Juan , Oh, Hwamee , Pascual, Belén , Gordon, Brian A. , Rosa-Neto, Pedro , Pascoal, Tharick Ali

Mayo Clinic

Alzheimer's & Dementia | January 8, 2026 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_106862 Get It

Abstract Background Studies suggest that sex influences the deposition of tau in the human brain and impacts on the relationship of tau with AD‐related outcomes. The aim of this study is to evaluate the extent to which sex influences PET‐Tau related outcomes and whether this effect is related to specific tau PET tracers. Method We assessed 456 participants from the HEAD study (mean age = 66.07 ± 13.05). All individuals had available Tau‐PET with Flortaucipir and MK6240, Aβ‐PET and a subset had plasma p ‐Tau 217 ( n = 352). We conducted a linear regression analysis between sex and PET Tau to evaluate the direct influence of sex on PET Tau SUVR. Next, we assessed whether sex affected the relationship between Tau PET (in BRAAK I‐II, III‐IV, V‐VI regions) and Aβ‐PET or plasma p ‐Tau 217 by adding an interaction term in the associations. All analyses were corrected by age, clinical classification, and amyloid burden. Result No significant differences were observed between male and female SUVR levels in either Flortaucipir and MK6240 tracers (Figure 1). However, when assessing the relationship between Aβ‐PET and Tau, a statistically significant interaction with sex was seen between MK6240 in BRAAK III‐IV (β = 0.160, p = 0.020 ; Figure 2) and BRAAK V‐VI regions (β = 0.196, p = 0.008; Figure 2), with women having a stronger association. Furthermore, we found an interaction between sex and p ‐tau217 on Tau PET SUVR in BRAAK regions I‐II using MK6240 or Flortaucipir (β = ‐0.184, p = 0.014; β = ‐0.266, p = 0.002; Figure 3) indicating that women present a weaker relationship between p ‐tau217 and Tau PET. Conclusion Our results did not show any differences between men and women in Tau‐PET SUVR uptake across tau tracers. However, we found that sex affected how Aβ‐PET and plasma p ‐tau217 were associated with Tau‐PET uptake. Further studies are needed to elucidate the underpinnings of the link between sex and the association between these biomarkers.
Investigating the Use of the Fast Health Care Interoperability Resources (FHIR) Standard to Support Data Activities Across the PCORnet® Infrastructure: Lessons Learned From the FHIR Pilots of the Coordinating Center for PCORnet®
Marsolo, Keith S, Louzao, Darcy, Hart, Kim Ward, Shrader, Peter, Hawley, Jeffrey , Delacqua, Francesco, Thomas, E D, Wick, Joseph, Chamberlain, Alanna M., JONES, WILLIAM S., Rothman, Russell L., Harris, Paul A., Cheng, Alex C., Marsolo, Keith , Hart, Kim, Thomas, Ellis, Wick, Joseph J., Chamberlain, Alanna M. , Rothman, Russell L. , Harris, Paul A. , Cheng, Alex

Mayo Clinic

Medical Care | January 8, 2026 | Volume: 64 | Issue: 3S | Pages: S233-S241

10.1097/mlr.0000000000002236 | PMID 41504752 Get It

Background: Institutions that participate in PCORnet ® transform their local electronic health record (EHR) data into the PCORnet ® Common Data Model (CDM), which is then used to generate data extracts for PCORnet ® Studies. PCORnet ® Studies can also include institutions that do not participate in PCORnet, and for these organizations, the cost of instantiating a PCORnet ® CDM can be prohibitive. Fast Health care Interoperability Resources (FHIR) provides an alternative method of obtaining EHR data. Objective: To determine whether data obtained through FHIR might be a viable study solution for those sites that do not participate in PCORnet. ® This mixed-methods project had 2 objectives: (1) survey sites participating in PCORnet on the availability of FHIR (FHIR survey); (2) compare the coverage of a FHIR-based data extract using REDCap with one from the PCORnet ® CDM across 3 sites (FHIR extract). Methods: (1) FHIR survey: A series of questions were asked about the use of FHIR in a production capacity. (2) FHIR extract: REDCap FHIR and PCORnet ® CDM extracts were created based on study variables from 2 prior PCORnet ® Studies. Data were extracted for 40 patients and concordance measures were computed between the 2 sources. Results: (1) FHIR survey: Of responding organizations, 73% (n=49) reported that FHIR was deployed in a production capacity. (2) FHIR extract: Results were highly variable. Cohen kappa ranged from 0.01 to 0.76 for certain diagnoses, 0.24 to 0.84 for laboratory results, and 0.1 to 0.87 for medications. Conclusions: Despite differences in data, certain studies may be well-suited for FHIR-based extracts.
Multiple Myeloma, Version 5.2026, NCCN Clinical Practice Guidelines In Oncology
Kumar, Shaji K., Adekola, Kehinde , Anderson, Larry , Costello, C. L., D’Angelo, Christopher R. , Elsedawy, Noura, Godara, Amandeep , Godby, Kelly, Hillengass, J, Holmberg, Leona, Htut, Myo , Huff, Carol Ann , Hultcrantz, Malin , Kang, Yubin , Larson, Sarah, Lee, Hans Chulhee, Liedtke, Michaela , Martin, Thomas, Omel, James, Robinson, Timothy J., Rosenberg, Aaron, Sherbenou, Daniel, Suvannasankha, Attaya, Valent, Jason , Varshavsky‐Yanovsky, Asya, Ye, J Christine, Kovach, Emily, Kumar, Rashmi , Kumar, Shaji , Callander, Natalie S. , Baljević, Muhamed , Baz, Rachid , Campagnaro, Erica , Costello, Caitlin , Derman, Benjamin A. , Devarakonda, Srinivas , Hillengass, Jens, Holmberg, Leona , Kang, Yubin , Larson, Sarah, Lee, Hans C. , Rosenberg, Aaron , Sarosiek, Shayna , Schroeder, Mark A. , Sherbenou, Daniel W , Suvannasankha, Attaya , Valent, Jason Neil , Vogl, Dan T. , Kovách, E

Mayo Clinic

Journal of the National Comprehensive Cancer Network | January 8, 2026 | Volume: 24 | Issue: 1 | Pages: No page available

10.6004/jnccn.2026.0001 | PMID 41671464 Get It

The treatment landscape for multiple myeloma (MM) is evolving rapidly and includes several new options. The management must be tailored to the individual. The NCCN Guidelines for MM provide a framework to base decisions regarding diagnosis, workup, treatment, and follow-up of both newly diagnosed and previously treated relapsed/refractory MM. This manuscript outlines the recommendations from NCCN Guidelines for MM specific to newly diagnosed MM (NDMM).
Creating a multi‐centre Amyloid PET dataset for DLB patients: Design and Methodology
Bollack, Ariane, Shekari, Mahnaz , Frisoni, Giovanni B, Hanseeuw, Bernard J, Lowe, Val J. , Collij, Lyduine E., Buckley, Christopher, Thomas, A. Goldzier, O'Brien, John T, Farrar, Gill , Bollack, Ariane , Orso, Beatrice , Shekari, Mahnaz , Boccalini, Cecilia , Garibotto, Valentina , Frisoni, Giovanni B. , Quenon, Lisa , Hanseeuw, Bernard , Collij, Lyduine , Buckley, Christopher

Mayo Clinic

Alzheimer's & Dementia | January 8, 2026 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_106683 Get It

Abstract Background Dementia with Lewy Bodies (DLB) is often misdiagnosed or conflated with Alzheimer's Disease (AD) due to overlapping clinical presentations and neuropathological features. The presence of AD‐like features correlates with accelerated cognitive decline and a worse overall prognosis. Compared to AD, studies suggest that amyloid uptake in DLB may spare the occipital lobe. This project aims to investigate whether amyloid PET could be leveraged to differentiate between AD and DLB patients, with the goal of improving diagnostic accuracy and supporting patient stratification and safety in anti‐amyloid trials. Method This study involves collaboration across six centres (University of Geneva, BioFINDER, AMPLE, AMYPAD PNHS, MCSA, GEHC), each contributing amyloid PET imaging data from patients diagnosed with DLB based on clinical or neuropathological assessments. Moreover, each center provided an additional subset of AD and healthy controls, then matched to DLB samples based on age/sex/APOE genotype/education for comparison. A sub analysis will be performed on patients with evidence of both DLB and AD markers. Given the relatively small sample size, key aspect of the methodological approach is to reduce technical sources of variability. The processing workflow includes rigorous quality control, formatting, normalisation to MNI space, harmonisation (differential smoothing), and MRI‐based segmentation. Result The dataset currently includes amyloid PET scans (acquired using [ 11 C]PiB, [ 18 F]Flutemetamol or [ 18 F]Florbetapir) and MRI scans from ∼130 DLB patients, along with ∼150 AD patients and ∼150 controls. In addition, 99 patients positive for the CSF α‐Synuclein Seeding Amplification Assay were included. Patient data were anonymized, and a harmonised database was created, including demographic characteristics, clinical history, and results from neuropsychological assessments. Conclusion The creation of a standardized, multi‐centre amyloid PET dataset for DLB will enable the study of amyloid PET patterns at the global, regional and voxel level, in comparison with uptake in AD patients and controls. This dataset will serve as a valuable resource for investigating the neuropathological underpinnings of DLB, improving diagnostic accuracy, and potentially guiding patient stratification in anti‐amyloid trials. Efforts to integrate [ 18 F]Florbetaben and additional data are ongoing.
Debunking myths in facial pain diagnosis for the pain practitioner
Schuster, Nathaniel M. , Argoff, Charles E. , Barad, Meredith , Kesayan, Tigran , Kissoon, N., Narouze, Samer , Qian, Xiang , Romero-Reyes, Marcela, Yuan, Hsiangkuo , Narouze, Samer , Schuster, Nathaniel M , Barad, Meredith J , Yuan, Hsiangkuo , Kissoon, Narayan , Romero‐Reyes, Marcela

Mayo Clinic

Regional Anesthesia & Pain Medicine | January 8, 2026 | Volume: No volume available | Issue: No issue available | Pages: rapm-2025-107382

10.1136/rapm-2025-107382 | PMID 41506700 Get It

Facial pain disorders, most notoriously trigeminal neuralgia, cause substantial suffering, functional impairment, disability, and impaired quality of life. However, most pain medicine practitioners have had only limited education on the evaluation, diagnosis, and treatment of facial pain. Furthermore, this limited education often contains commonly held myths about facial pain diagnosis. These myths can result in misdiagnoses that lead to ineffective medications, interventions, or surgeries and prolonged pain. Therefore, the American Society of Regional Anesthesia and Pain Medicine’s Headache and Facial Pain Special Interest Group convened a multidisciplinary group of neurologists, anesthesiologists, and dentists to identify and dispel pervasive myths in facial pain diagnosis.
Tau‐PET and plasma GFAP association in cognitively unimpaired Aβ‐PET negative individuals
Saha, Pampa , Povala, Guilherme, Ferreira, Pamela C.L., Amaral, Lívia , Karikari, Thomas K, Oliveira, Markley Silva , Rocha, Andreia, Felix, Cynthia, Medeiros, Marina Scop , Soares, Carolina, Masdeu, Joseph C. , Tudorascu, Dana , Soleimani‐Meigooni, David, Fortea, Juan M., Lowe, Val J. , Oh, Hwamee , Gordon, Brian A., Rosa‐Neto, Pedro, Baker, Suzanne L. , Bellaver, Bruna , Povala, Guilherme , Ferreira, Pâmela C.L. , Bauer‐Negrini, Guilherme , Lussier, Firoza Zubeida , Karikari, Thomas K. , Rodrigues, Matheus Scarpatto , Felix, Cynthia , Ruppert, Emma Patrice , Soares, Carolina , Masdeu, Joseph C , Soleimani‐Meigooni, David N. , Fortea, Juan , Pascual, Belén , Gordon, Brian A. , Rosa-Neto, Pedro , Pascoal, Tharick Ali

Mayo Clinic

Alzheimer's & Dementia | January 8, 2026 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_105935 Get It

Abstract Background We showed that astrocyte reactivity, as measured by plasma GFAP levels, influences Aβ mediated tau PET pathology in cognitively unimpaired (CU) Aβ‐positive individuals. However, the link between GFAP and tau PET in individuals without detectable Aβ pathology remains elusive. The aim of the current study is to investigate the association between plasma GFAP and tau PET in CU Aβ PET‐negative individuals. Method We studied 147 CU Aβ PET‐negative participants from the HEAD cohort with plasma GFAP and p ‐tau217, as well as tau PET Flortaucipir and MK6240 data. Aβ positivity was determined by Aβ PET visual reading and Centiloid 12. Voxel‐wise linear regression models adjusted for age and sex tested the association of plasma GFAP and p ‐tau217 with tau PET. Further, the associations of plasma GFAP with peak tau PET SUVR values extracted from voxel‐wise association were fitted with a linear regression model adjusted for age and sex. Result Voxel‐wise analysis showed that plasma GFAP levels, but not plasma p ‐tau217 levels, were associated with tau PET in the medial temporal lobe (e.g., amygdala, entorhinal cortex, hippocampus) predominantly for Flortaucipir tau PET [Figure 1A, B, C, D]. The association between plasma p ‐tau217 and tau PET was weak in Aβ‐negative individuals. These results were similar when Aβ positivity was defined based on Centiloid 12. Furthermore, plasma GFAP and peak tau PET SUVR of Flortaucipir showed stronger association than that of MK6240 [Flortaucipir: β=0.4017, p <0.0001; MK6240: β=0.194, p = 0.0424; Figure 2A, B]. Conclusion We found an association between GFAP levels and tau PET uptake in individuals not expected to exhibit high levels of tau tangle‐related tracer uptake. Further analysis will be designed to elucidate the underpinning of this association, which could represent low levels of tau pathology, astrogliosis, or other factors.
Placental hypoxia and oxidative stress responses to smokeless tobacco use in Alaska Native participants in the MAW study
Kennedy, Katherine M. , Wallace, Jessica G. , Thomas, Timothy K., Murphy, Neil J. , Hughes, Christine A. , Holloway, Alison C. , Sloboda, Deborah M. , Patten, Christi A. , Holloway, Alison C , Koller, Kathryn R. , Flanagan, Christie A.

Mayo Clinic

Canadian Journal of Physiology and Pharmacology | January 7, 2026 | Volume: 104 | Issue: No issue available | Pages: 1-7

10.1139/cjpp-2025-0271 | PMID 41499767 Get It

Cigarette smoking is associated with numerous adverse pregnancy outcomes, due in part to polycyclic aromatic hydrocarbons and free radicals produced by combustion. Less is known about the impact of smokeless tobacco (ST) use during pregnancy. Alaska Native women report higher rates of cigarette and ST use during pregnancy than non-Native women. We investigated oxidative stress and hypoxia pathways in term placentae from Alaska Native women who did (commercial or iqmik; n = 10) or did not ( n = 18) use ST during pregnancy. Despite substantial maternal exposure to nicotine, placentae of women who used ST had similar mRNA levels of antioxidant enzymes and markers of hypoxia compared to those who did not use tobacco. Although mRNA levels of angiogenesis markers vegf and vegfr2 were similar between groups, vegfr1 mRNA levels are increased in placentae of women using ST compared to women who did not use tobacco. Together these results suggest that, while ST use may not have as significant an effect on oxidative stress pathways in the placenta as cigarette smoking, an effect is present. It is not clear what this limited effect may have on the developing fetus.
Spectrum, prevalence, and clinical correlates of PPM1D mutations in patients with clonal hematopoiesis and clonal cytopenias
Badar, Talha , Marando, Ludovica , Latorre-Crespo, Eric, Oliva, Francyess Denis, Lin, Chenyu , McCormick, Benjamin J. , Kettani, Mobachir El , Shah, Kashish, Kusne, Yael , Jamy, Omer , Diebold, Kendall , Coltoff, Alexander , Finke, Christy M. , Foran, James M. , Kharfan‐Dabaja, Mohamed A. , Fan, Yao‐Shan, Jiang, Liuyan , He, Rong , Thomas, M. , Patel, Anand , Viswanatha, D., Shah, Maleeha, Mangaonkar, Abhishek A. , Kirschner, Kristina , Al‐Kali, Aref , Gangat, Naseema, Litzow, Mark R. , Patnaik, Mrinal M. , Latorre‐Crespo, Eric , Latorre, Eric , Lin, Chenyu , El Kettani, Mobachir , Kusne, Yael N , Jamy, Omer , Kharfan-Dabaja, Mohamed A , He, Rong , Patel, Anand , Viswanatha, David, Shah, Mithun V , Saliba, Antoine N , Kirschner, Kristina , Al-Kali, Aref , Gangat, Naseema , Litzow, Mark R. , Patnaik, Mrinal , Badar, Talha , Lasho, Terra L. , Thomas, Miles, Saliba, Antoine N. , Gangat, Naseema

Mayo Clinic

Blood Advances | January 7, 2026 | Volume: 10 | Issue: 5 | Pages: 1746-1755

10.1182/bloodadvances.2025018031 | PMID 41499760 Get It

Abstract TP53 and PPM1D are key regulators of DNA damage response and repair, and somatic mutations in these genes often co-occur in hematopoietic cells, expanding under genotoxic stress. Unlike TP53 mutations, where mechanisms of progression are defined, pathways underlying clonal fitness and transformation in PPM1D mutant cells remain unclear. In collaboration with 5 academic institutions, we analyzed the clinical and molecular landscape of 337 patients with clonal hematopoiesis (CH) and clonal cytopenia of undetermined significance (CCUS) across 4 genotypes: PPM1Dmt/TP53wt (n = 170 [50%]), PPM1Dmt/TP53mt (n = 25 [7%]), TP53mt/PPM1Dwt (n = 17 [5%]), and TP53wt/PPM1Dwt (n = 125 [38%]). All PPM1D variants were truncating, located in exon 6 of the gene, with a median variant allele frequency (VAF) of 6% (range, 0.3%-64%). The PPM1Dmt/TP53mt genotype was most frequently encountered in therapy-related CH/CCUS (t-CH/t-CCUS; 80%, 66.5%, 76.5%, and 19%; P ≤ .001) and had a shorter time interval to detection from last genotoxic exposure (6.2, 5.9, 11.25, and 24.5 months; P ≤ .001) compared with PPM1Dmt/TP53wt, TP53mt/PPM1Dwt, and TP53wt/PPM1Dwt genotypes, respectively. Acknowledging the short follow-up duration, rates of malignant transformation were lower in the PPM1Dmt/TP53wt (2%) and PPM1Dmt/TP53mt (4%) groups compared with PPM1Dwt/TP53wt (12%) and PPM1Dwt/TP53mt (17%) groups (P ≤ .001), respectively. In summary, PPM1D mutations are frequently observed in t-CH/t-CCUS, with low median VAFs, and are associated with low rates of progression, even when comutated with TP53.
The Utility of Artificial Intelligence Platforms for Post‐Operative Mohs Micrographic Surgery Questions: A Blinded Expert Panel Evaluation
Shelton, Eva, Patel, Janmesh , Alam, Murad , Bar, Anna, Rohrer, Thomas A., Ruiz, Emily S. , Wysong, Ashley, Yu, Siegrid S., Tolkachjov, Stanislav N., Shelton, Eva M , Bar, Anna, Tolkachjov, Stanislav N.

Mayo Clinic

International Journal of Dermatology | January 7, 2026 | Volume: 65 | Issue: 6 | Pages: 1272-1275

10.1111/ijd.70232 | PMID 41498280 Get It